infohep news

• Treatment in liver transplanted

  Sofosbuvir + ribavirin is safe and effective for people with hepatitis C who have advanced liver disease

  Liz Highleyman / 17 April 2014

  Sofosbuvir plus ribavirin is a safe option that can lead to sustained response in people with advanced liver disease including those with decompensated cirrhosis and portal hypertension, and people who experience severe hepatitis ...

• Interferon-free regimens

  BMS combination cures 90% of genotype 1b hepatitis C in 24 weeks

  Keith Alcorn / 17 April 2014

  A combination of two direct-acting antivirals developed by Bristol-Myers Squibb (BMS) cured 90% of previously untreated people with genotype 1b hepatitis C infection in 24 weeks, without the need for pegylated interferon ...

• Sofosbuvir/ledipasvir co-formulation cures more than 90% of treatment-naive and retreated genotype 1 patients

  Liz Highleyman / 16 April 2014

  A co-formulation of sofosbuvir and ledipasvir taken for as little as eight to twelve weeks produced high sustained response rates across the board for participants in the phase 3 ION trials, including ...

• Treatment guidelines

  European liver specialists recommend use of newest hepatitis C drugs

  Keith Alcorn / 12 April 2014

  The European Association for the Study of the Liver (EASL) has issued new guidelines for the treatment of hepatitis C which recommend that wherever possible, patients should be treated with ...

• Transmission and prevention

  Treatment for prevention for hepatitis C in French drug users could cut HCV prevalence by two-thirds in 10 years

  Keith Alcorn / 12 April 2014

  A combination of increased testing, improved linkage to care and treatment immediately after diagnosis with interferon-free regimens has the potential to substantially reduce the incidence and prevalence of hepatitis C virus ...